As many as 45% of patients with gastroesophageal reflux disease (GERD) still have symptoms after receiving a once-daily proton pump inhibitor (PPI) therapy. A recent study by Jason Abdallah and colleagues at
MetroHealth Medical Center, Case Western Reserve University School of Medicine, utilized survey, pH, and other data. Although a small trial, the findings showed most GERD patients who failed PPI once daily appeared to have an overlap with functional esophageal disorders (either reflux hypersensitivity or functional heartburn). The results support the hypothesis that PPI failure is primarily driven by esophageal hypersensitivity.